Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH”s National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network (CoVPN). Myron Cohen, MD, director of UNC’s Institute for Global Health and Infectious Diseases and co-principal investigator of CoVPN, helped to design and oversee the trial. David Wohl, MD, UNC professor of infectious diseases, served as the UNC site principal investigator, working with several skilled nursing facilities in North Carolina.
Read more in the UNC Health and UNC School of Medicine Newsroom.